Mark Danese, MHS, PhD
Mark Danese, MHS, PhD, has over 20 years of experience in epidemiology and outcomes research. He received his masters degree in Biostatistics in 1997, and his doctorate in Epidemiology in 1999, both from The Johns Hopkins University. Beginning in 2000, he worked for Amgen, Inc., in both the Global Health Economics and Global Epidemiology departments. In December 2003, founded Outcomes Insights, Inc. Dr. Danese’s expertise is in the design and analysis of studies using observational data, creation of budget impact and cost-effectiveness models, and the design of population-based simulation models. He has over 50 peer-reviewed manuscripts published in a variety of journals.
Dr. Danese is a collaborator with the Observational Health Data Science and Informatics (OHDSI) collaborative, helping to develop open-source tools to improve the conduct of observational studies. He leads the Medicare ETL Working group for OHDSI, and is working with the National Cancer Institute to develop an ETL process for the Surveillance Epidemiology and End Results (SEER) data.
Duryea R, Danese MD. Human Readable Expression of Structured Algorithms for Describing and Storing Clinical Study Criteria and for Generating and Visualizing Queries. AMIA 2015 Summit on Clinical Research Informatics. http://knowledge.amia.org/amia-59309-cri2015-1.2002246/t-001-1.2003843/a-001-1.2003852/a-001-1.2003853/ap-001-1.2003854
Danese MD, Griffiths RI, Gleeson M, Satram-Hoang S, Knopf K, Mikhael J, Reyes C. An Observational Study of Outcomes After Initial Infused Therapy in Medicare Patients Diagnosed with Chronic Lymphocytic Leukemia. Blood. 2011;117:3505-13. PMID: 21190994.
Griffiths RI, Gleeson ML, Danese MD, O’Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health. 2012 Jul-Aug;15(5):656-63. doi: 10.1016/j.jval.2012.03.1388. PubMed PMID: 22867774.
Griffiths RI, O’Malley CD, Herbert RJ, Danese MD. Misclassification of incident conditions using claims data: impact of varying the period used to exclude pre-existing disease. BMC Med Res Methodol. 2013 Mar 6;13:32. doi: 10.1186/1471-2288-13-32. PubMed PMID: 23496890; PubMed Central PMCID: PMC3602098.
Danese MD, O’Malley C, Lindquist K, Gleeson M, Griffiths RI. Prevalence and Incidence of Comorbid Conditions in Older Women with Breast Cancer. Ann Oncol. 2011 PubMed PMID: 22039090.
Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):914-21. PMID: 21735509.
Griffiths RI, Gleeson ML, Valderas JM, Danese MD. Impact of undetected comorbidity on treatment and outcomes of breast cancer. Int J Breast Cancer. 2014;2014:970780. doi: 10.1155/2014/970780. Epub 2014 Feb 13. PubMed PMID: 24688795; PubMed Central PMCID: PMC3943288.